Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Follow-On Biologics: Defeat For Waxman, Win For Health Reform

This article was originally published in The Pink Sheet Daily

Executive Summary

Lopsided committee vote suggests that lengthy exclusivity is here to stay, which means that big pharma can get more comfortably behind the broader reform effort.
Advertisement

Related Content

Rep. Pallone’s Energy And Commerce Win Is Salve For Generics
Waxman’s Congressional Exclusivity Set To Expire, But There Will Be No Equivalents
How "Clean" Will PDFUA V Be? Rep. Pitts Explains His Vacuuming Technique
How "Clean" Will PDFUA V Be? Rep. Pitts Explains His Vacuuming Technique
Teva Launching "6 vs 12" Campaign On Follow-On Biologics
Teva Launching "6 vs 12" Campaign On Follow-On Biologics
"Pay For Delay" Legislation Gaining Speed
The 77% Solution: Obama Rx Drug Overpayment Claim Culled From McKinsey Report
Follow-on Biologics Go Back To The Future: Senate Cmte. Endorses 12 Years of Brand Exclusivity
Follow-on Biologics Go Back To The Future: Senate Cmte. Endorses 12 Years of Brand Exclusivity

Topics

Advertisement
UsernamePublicRestriction

Register

PS069776

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel